Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.…
Gyre Therapeutics, Inc. (GYRE) Tops Q3 Earnings and Revenue Estimates
Gyre Therapeutics (NASDAQ: GYRE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 625 employees.
The shares were at 4.210 USD on 20 November 2026, down 41.6% over 52 weeks. Its 52-week range is 4.000 USD to 9.140 USD: the price is 53.9% below the high and 5.3% above the low.
Its market capitalisation is 460.79M USD.
Gyre Therapeutics reports return on equity of 4.7%, an operating margin of -16.6% and revenue up 0.7% year over year.
It holds more cash than debt, a net cash position of 67.03M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 11 March 2027.